Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1407511
This article is part of the Research Topic Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies Volume II View all 5 articles

Drug repositioning in thyroid cancer: From Point mutations to Gene Fusions

Provisionally accepted
David Sánchez-Marín David Sánchez-Marín 1Macrina Beatriz S. Cázares Macrina Beatriz S. Cázares 2Manuel González-del Carmen Manuel González-del Carmen 3Alma D. Campos-Parra Alma D. Campos-Parra 4*
  • 1 National Autonomous University of Mexico, México City, México, Mexico
  • 2 Autonomous University of San Luis Potosí, San Luis Potosí, San Luis Potosi, Mexico
  • 3 Universidad Veracruzana, Xalapa, Mexico
  • 4 Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Mexico

The final, formatted version of the article will be published soon.

    The diagnosis of thyroid cancer (TC) has increased dramatically in recent years.Papillary TC is the most frequent type and has shown good prognosis.Conventional treatments for TC are surgery, hormonal therapy, radioactive iodine, chemotherapy, and targeted therapy. However, resistance to treatments is well documented in almost 20% of all cases. Genomic sequencing has provided valuable information to help identify variants that hinder the success of chemotherapy as well as to determine which of those represent potential druggable targets. There is a plethora of targeted therapies for cancer, most of them directed towards point mutations, however, chromosomal rearrangements that generate fusion genes are becoming relevant in cancer but have been less explored in TC.Therefore, it is relevant the identification of new potential inhibitors for genes that are recurrent in the formation of gene fusions. In this review, we focus on describing potentially druggable variants and propose both point variants and fusion genes as targets for drug repositioning in TC.

    Keywords: thyroid cancer, variants, repurposed drugs, Gene fusions, mutations

    Received: 26 Mar 2024; Accepted: 16 Apr 2024.

    Copyright: © 2024 Sánchez-Marín, Cázares, González-del Carmen and Campos-Parra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Alma D. Campos-Parra, Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.